Ironwood Pharmaceuticals (IRWD) Interest Expenses (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Interest Expenses data on file, last reported at $9.1 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 13.27% year-over-year to $9.1 million; the trailing twelve-month figure through Mar 2026 stood at $31.4 million (up 456.22% YoY), and the FY2025 full-year result was $126.3 million, up 18.84% from the prior year.
• Interest Expenses advanced to $9.1 million in Q1 2026, from $5.5 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $10.2 million in Q4 2023 to a low of -$19.3 million in Q4 2024.
• A 5-year average of $4.3 million and a median of $7.2 million in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses surged 3212.23% in 2023 and tumbled 289.77% in 2024, its largest moves.
• Tracing IRWD's Interest Expenses over 5 years: stood at -$327000.0 in 2022, then surged by 3212.23% to $10.2 million in 2023, then plunged by 289.77% to -$19.3 million in 2024, then surged by 128.34% to $5.5 million in 2025, then surged by 67.02% to $9.1 million in 2026.
• Business Quant data shows IRWD's Interest Expenses at $9.1 million in Q1 2026, $5.5 million in Q4 2025, and $8.4 million in Q3 2025.